弥漫性大B细胞淋巴瘤IL-6和VEGF表达水平与化疗耐药的相关性

Correlation between expression levels of cytokines IL-6 and VEGF with chemotherapy resistance in diffuse large B-cell lymphoma

目的探讨弥漫性大B细胞淋巴瘤(DLBCL)患者血清白细胞介素6(IL-6)、血管内皮生长因子(VEGF)的表达及与化疗耐药之间的相关性。方法采用酶联免疫吸附试验(ELISA)分别测定16例化疗耐药患者(化疗耐药组)、20例化疗敏感患者(化疗敏感组)治疗前后和15例健康者(对照组)血清IL-6、VEGF水平。结果化疗耐药组患者血清IL-6、VEGF初治前表达水平明显高于化疗敏感组患者初治前和对照组(P<0.05),治疗缓解后明显低于治疗前(P<0.05)。DLBCL复发耐药时,患者血清中的IL-6、VEGF又高于缓解时水平(P<0.05)。化疗耐药组Ⅲ～Ⅳ期患者治疗前、复发耐药时IL-6、VEGF水平明显高于Ⅰ～Ⅱ期患者(P<0.05)。结论 DLBCL患者血清IL-6、VEGF表达水平的变化,提示其可以作为观察DLBCL病情变化的检测指标,可能与DLBCL细胞耐药有关。

Objective To investigate the correlation between expression levels of serum cytokines IL-6 and VEGF in the patients with diffuse large B-cell lymphoma（DLBCL） and chemotherapy resistance.Methods The levels of serum IL-6 and VEGF were measured by ELISA in 16 patients with chemotherapy resistance and 20 cases with chemotherapy-sensitive before and after treatment,and 15 healthy people（control group）.Results The expression levels of serum IL-6 and VEGF before treatment in DLBCL patients with chemotherapy resistance were significantly higher than those in DLBCL patients with chemotherapy sensitive and the normal control group（P0.05）,however,which after treatment in DLBCL patients with chemotherapy resistance were significantly lower than those of before treatment（P0.05）.The levels of serum IL-6 and VEGF in patients with DLBCL recurrence to drug resistance were higher than those during remission（P0.05）.Before treatment,the expression level of serum IL6,VEGF in the patients with Ⅲ-Ⅳ stage in chemotherapy resistant group was significantly higher than that in ones with Ⅰ-Ⅱ stage（P 0.05）.Conclusion The change of the expression levels of serum IL-6,VEGF in DLBCL patients could be considered as the detective markers for condition observation,and may be involved in drug resistance of DLBCL.